MediSix Therapeutics

We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.